NEW YORK (TheStreet) -- The evolution of diabetes treatment will continue to improve as the years go on. TheStreet's Jill Malandrino is with Nadav Kidron, CEO of Oramed Pharmaceuticals (ORMP), to discuss the company's new treatment.
Kidron said there are three stages in which patients with Type II diabetes act to treat it: changing their diet and lifestyle, taking medicine orally, and finally, using insulin pumps or injections.
Oramed has created an ingestible insulin pill that patients would take in the second stage of their process.
By administering the drug early enough, Kidron said, the patient's need to use insulin injections or pumps would be postponed.He added that oral administration is much better than injection. By performing the latter, the insulin is injected directly into the bloodstream, whereas an ingestible pill goes first to the liver, which regulates the secretion of insulin into the bloodstream. Kidron concluded that it's an exciting time, as the company is expected to complete a Phase II trial for the drug by the end of the year, and is also working on a similar project for Type I diabetes. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV